« Return to News | Technology Solutions

Savara joins SAFE-BioPharma

Tuesday, November 22, 2011 11:25 AM
Savara Pharmaceuticals, an inhalation drug development company, has joined SAFE-BioPharma Association. SAFE-BioPharma manages the SAFE-BioPharma digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.
 
Savara, which focuses on improving existing small molecule medicines through advanced formulation and delivery technologies across a number of therapeutic areas including asthma, cystic fibrosis and lung cancer, is incorporating the SAFE-BioPharma standard to improve its overall operating efficiencies.
 
“We are about to enter clinical trials and wanted a tool to help us eliminate paper from our systems, save time and become more efficient. For us, SAFE BioPharma is the logical choice,” said Chris Marich, vice president, business operations, Savara.
 
SAFE-BioPharma digital signatures are uniquely linked to the individual’s authenticated identity and are more secure and legally-binding than conventional electronic signatures. They are recognized by regulatory agencies throughout the U.S. and Europe.
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.